OLA
ANIP icon

Oliver Luxxe Assets’s ANI Pharmaceuticals ANIP Stock Holding History

Oliver Luxxe Assets’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.97M Sell
23,738
-7,782
-25% -$624K 0.29% 103
2026
Q1 		$2.42M Buy
31,520
+8,422
+36% +$657K 0.36% 108
2025
Q4 		$1.82M Buy
+23,098
New +$2M 0.28% 124

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oliver Luxxe Assets's ANIP Position: Q2 2026 in Review

Oliver Luxxe Assets reduced its ANI Pharmaceuticals (ANIP) stake by 25% in Q2 2026, selling an estimated $624K and leaving 23,738 shares worth $1.97M. The position accounts for 0.29% of the portfolio, ranked #103.

Oliver Luxxe Assets first reported a position in ANIP in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.42M in Q1 2026. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Oliver Luxxe Assets held 23,738 shares of ANI Pharmaceuticals worth $1.97M as of Q2 2026.
  • Oliver Luxxe Assets sold 7,782 ANI Pharmaceuticals shares in Q2 2026, an estimated $624K.
  • ANI Pharmaceuticals made up 0.29% of Oliver Luxxe Assets's portfolio in Q2 2026, its #103 holding.
  • Oliver Luxxe Assets first reported a position in ANI Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Oliver Luxxe Assets's ANI Pharmaceuticals position peaked at $2.42M in Q1 2026.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Oliver Luxxe Assets's 13F filing for Q2 2026, filed 9 Jul 2026.